ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 million) from BB Pureos Bioventures (“Pureos”) in an extension of its Series B bringing the total raised in this round to €54 million in capital (approximately $64 million).
The newly added capital underscores the broad potential of ImCheck’s butyrophilin superfamily-focused pipeline and the progress the company has achieved in the ongoing EVICTION (NCT04243499) Phase I/IIa clinical trial for the company’s first-in-class gamma9 delta2 (γ9δ2) T cell-activating monoclonal antibody ICT01 (anti-butyrophilin 3A). In addition to supporting EVICTION, the funding will also accelerate the development of the company’s pre-clinical portfolio of antibody candidates in immuno-oncology, auto-immune and infectious disease indications.
This press release is only available in English.